Tributary Capital Management’s Q2 2026 letter said Abbott Laboratories’ nutrition recovery is slow and competition is intensifying in Structural Heart and continuous glucose monitoring. It said those pressures appear to outweigh the growing tailwind in electrophysiology.
Abbott was highlighted in the strategy’s Q2 letter. Its shares closed at $103.49 on Sept. 23, 2026; the article reports declines of 7.27% over the previous month and 22.37% over 52 weeks. It also says 86 hedge fund portfolios held Abbott at the end of Q2, compared with 73 in the previous quarter.
